((1r,4r)-4-aminocyclohexyl)methanol | 30134-98-6

• 物质功能分类: 有机原料 - 氨基化合物 - 环烷胺、芳香单胺、芳香多胺及其衍生物和盐
• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: ((1r,4r)-4-aminocyclohexyl)methanol
• 英文别名: ((1s,4s)-4-aminocyclohexyl)methanol；(cis)-(4-aminocyclohexyl)methanol；((1S,4S)aminocyclohexyl)methanol；(cis-4-Aminocyclohexyl)methanol；cis-(4-aminocyclohexyl)methanol
• CAS: 30134-98-6
• 化学式: C₇H₁₅NO
• 分子量: 129.202
• InChiKey: GHUJZOFJZVGTSN-KNVOCYPGSA-N

物化性质

• 沸点：
  218.8±13.0 °C(Predicted)
• 密度：
  0.974±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  9.0
• 可旋转键数：
  1.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  46.25
• 氢给体数：
  2.0
• 氢受体数：
  2.0

反应信息

• 作为反应物：
  描述：

  ((1r,4r)-4-aminocyclohexyl)methanol 在 四(三苯基膦)钯 ammonium hydroxide 、 N-碘代丁二酰亚胺 、 sodium carbonate 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 23.0h， 生成 ((1S,4S)-4-(5-(3-(7-oxabicyclo[2.2.1]heptan-1-ylmethoxy)phenyl)-4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexyl)methyl methanesulfonate
  参考文献：
  名称：

  [EN] ETHER DERIVATIVES OF BICYCLIC HETEROARYLS
  [FR] DÉRIVÉS ÉTHERS D'HÉTÉROARYLES BICYCLIQUES

  摘要：

  这项发明涉及到式(I)的化合物，其中取代基如规范中所定义；制备这种化合物的方法；包含这种化合物的药物组合物；这种化合物作为药物；这种化合物用于治疗增殖性疾病。

  公开号：

  WO2011029915A1
• 作为产物：
  描述：

  cis 4-benzoylaminocyclohexanemethanol 在 盐酸 作用下， 生成 ((1r,4r)-4-aminocyclohexyl)methanol
  参考文献：
  名称：

  Synthesis of analogs of N-(2-chloroethyl)-N'-(trans-4-methylcyclohexyl)-N-nitrosourea for evaluation as anticancer agents

  摘要：

  The superior activity of N-(2-chloroethyl)-N'-(trans-4-methylcyclohexyl)-N-nitrosourea (MeCCNU) against advanced murine Lewis lung carcinoma in comparisons with the cis form and other nitrosoureas prompted the synthesis of a number of MeCCNU analogues, including several cis-trans pairs. The methyl group was replaced by a variety of substituents (CO2H, CH2CO2H, CO2Me, CH2OAc, CH2Cl, OMe); the trans-3-methylcyclohexyl, cis-2-methyl-1,3-dithian-5-yl, cis- and trans-2-methyl-1,3-dithian-5-yl-tetraoxide, and 1-methylhexyl (open-chain) analogues were also prepared. Preliminary tests against murine leukemia L1210 revealed therapeutic indices (ED50/LD10) ranging from 0.26 to 0.79; all but three analogues effected 50% cure rates at nontoxic doses, the open-chain analogue being one of the least active. In terms of therapeutic index, diequatorial (trans-4) isomers were, with one exception, as active as or, in four of the eight examples, somewhat more active than the corresponding axial-equatorial (cis-4) isomers. In this series, four of the five 2-fluoroethyl analogues prepared were clearly inferior to the corresponding 2-chloroethyl analogues.

  DOI：

  10.1021/jm00212a019

文献信息

• SERINE/THREONINE KINASE INHIBITORS
  申请人：GENENTECH, INC.

  公开号：US20150031674A1

  公开（公告）日：2015-01-29

  Compounds having the formula I wherein R 1 , R 2 , R 3 , R 4 , R 5 , R a , R b , R c , R d , R e , n, r, s and t are as defined herein and which compounds are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.

  具有公式I的化合物，其中R1、R2、R3、R4、R5、Ra、Rb、Rc、Rd、Re、n、r、s和t的定义如本文所述，并且这些化合物是PAK1的抑制剂。还公开了用于治疗癌症和过度增殖性疾病的组合物和方法。
• LIBRARIES OF DIVERSE MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME
  申请人：CYCLENIUM PHARMA INC.

  公开号：US20190153620A1

  公开（公告）日：2019-05-23

  The present disclosure relates to novel macrocyclic compounds and libraries thereof that are useful as research tools for drug discovery efforts. This disclosure also relates to methods of preparing these compounds and libraries and methods of using these libraries, such as in high throughput screening. In particular, these libraries are useful for evaluation of bioactivity at existing and newly identified pharmacologically relevant targets, including G protein-coupled receptors, nuclear receptors, enzymes, ion channels, transporters, transcription factors, protein-protein interactions and nucleic acid-protein interactions. As such, these libraries can be applied to the search for new pharmaceutical agents for the treatment and prevention of a range of medical conditions.

  本公开涉及新颖的大环化合物及其库，这些化合物可作为药物发现工作的研究工具。本公开还涉及制备这些化合物和库的方法，以及使用这些库的方法，例如在高通量筛选中的应用。特别是，这些库可用于评估现有和新鉴定的药理相关靶点的生物活性，包括G蛋白偶联受体、核受体、酶、离子通道、转运蛋白、转录因子、蛋白质相互作用和核酸-蛋白质相互作用。因此，这些库可应用于寻找用于治疗和预防各种医疗状况的新药物。
• [EN] HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROARYLES SERVANT D'INHIBITEURS D'IRAK, ET LEURS UTILISATIONS
  申请人：MERCK PATENT GMBH

  公开号：WO2017049068A1

  公开（公告）日：2017-03-23

  The present invention relates to compounds of Formula (I) and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.

  本发明涉及式(I)化合物及其药用可接受的组合物，作为IRAK抑制剂。
• [EN] LIBRARIES OF HETEROARYL-CONTAINING MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME<br/>[FR] BIBLIOTHÈQUES DE COMPOSÉS MACROCYCLIQUES CONTENANT HÉTÉROARYLE ET PROCÉDÉS POUR LEUR FABRICATION ET LEUR UTILISATION
  申请人：CYCLENIUM PHARMA INC

  公开号：WO2017049383A1

  公开（公告）日：2017-03-30

  The present disclosure relates to novel macrocyclic compounds and libraries thereof containing heteroaryl moieties that are useful as research tools for drug discovery efforts. The present disclosure also relates to methods of preparing these compounds and libraries and methods of using these libraries, such as in high throughput screening. In particular, these libraries are useful for evaluation of bioactivity at existing and newly identified pharmacologically relevant targets, including G protein-coupled receptors, nuclear receptors, enzymes, ion channels, transporters, transcription factors, protein-protein interactions and nucleic acid-protein interactions. As such, these libraries can be applied to the search for new pharmaceutical agents for the treatment and prevention of a range of medical conditions.

  本公开涉及新型大环化合物及其库，其中包含对药物发现工作有用的含杂环芳基团的化合物。本公开还涉及制备这些化合物和库的方法，以及使用这些库的方法，例如在高通量筛选中使用。特别是，这些库可用于评估现有和新鉴定的药理学相关靶点的生物活性，包括G蛋白偶联受体、核受体、酶、离子通道、转运蛋白、转录因子、蛋白质相互作用和核酸-蛋白质相互作用。因此，这些库可应用于寻找用于治疗和预防各种医疗状况的新药物。
• ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS
  申请人：Celgene Corporation

  公开号：US20170348315A1

  公开（公告）日：2017-12-07

  Provided herein are Aminopurine compounds of Formula I: or pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R 1 , R 2 , and R 3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing animal and human protozoal infections.

  本文提供了化合物I的氨基嘌呤：或其药用盐、互变异构体、同位素同质体或立体异构体，其中R1、R2和R3如本文所定义，包含有效量氨基嘌呤化合物的组合物，以及用于治疗或预防动物和人类原虫感染的方法。